SCHEMBL15034052

SCHEMBL15034052

CC1(C)CN(C(=O)c2ccc3ccccc3c2)CCN1C(=O)c1ncn(-c2cccc(Cl)c2)n1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 3/20 0.43
LMNA P02545 2/20 0.43
HPGD P15428 3/20 0.42
SLC6A7 Q99884 1/20 0.42
MGLL Q99685 2/20 0.41
GRM5 P41594 1/20 0.40
ALDH1A1 P00352 2/20 0.40
HTT P42858 2/20 0.40
NPSR1 Q6W5P4 2/20 0.40
MEN1 O00255 1/20 0.40
POLB P06746 1/20 0.40
KMT2A Q03164 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
MAPT P10636 2/20 0.39
AKR1C1 Q04828 1/20 0.39
NPC1 O15118 2/20 0.39
USP2 O75604 1/20 0.39
GAA P10253 1/20 0.39
ALOX15 P16050 1/20 0.39
HSD17B10 Q99714 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15019972 0.91 SLC6A7 (0.43) TSHRLMNAHPGDSLC6A7MGLL
SCHEMBL15034054 0.89 SLC6A7 (0.43) TSHRHPGDSLC6A7MGLLALDH1A1
SCHEMBL15020006 0.89 ALDH1A1 (0.44) HPGDSLC6A7GRM5ALDH1A1HTT
SCHEMBL15034095 0.89 ALDH1A1 (0.47) TSHRLMNAHPGDSLC6A7MGLL
SCHEMBL15034084 0.89 SLC6A7 (0.44) TSHRLMNAHPGDSLC6A7MGLL
SCHEMBL15034088 0.88 ALDH1A1 (0.46) TSHRHPGDSLC6A7MGLLALDH1A1
SCHEMBL15034105 0.88 HPGD (0.44) HPGDSLC6A7MGLLALDH1A1
SCHEMBL15034067 0.87 GRM5 (0.47) HPGDMGLLGRM5ALDH1A1
SCHEMBL15034089 0.87 MGLL (0.46) TSHRHPGDSLC6A7MGLLALDH1A1
SCHEMBL15034057 0.87 DRD3 (0.40) SLC6A7MGLLGRM5POLBMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8883789-B2 Piperazine derivatives and their use as positive allosteric modulators of mGluR5 receptors BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2014-11-11 US disclosed
US-8883789-B2 Piperazine derivatives and their use as positive allosteric modulators of mGluR5 receptors BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2014-11-11 US disclosed
US-20130158042-A1 NOVEL COMPOUNDS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2013-06-20 US disclosed
US-20130158042-A1 NOVEL COMPOUNDS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2013-06-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130158042-A1 NOVEL COMPOUNDS GRM5, GRIK5, GRM1 TSHR 886/4885LMNA 4835/4885HPGD 2696/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.